Safety and efficacy of adalimumab treatment in Greek children with juvenile idiopathic arthritis

Scandinavian Journal of Rheumatology

Volumn 40, Issue 2, 2011, Pages 101-107

  Trachana, M ^a   Pratsidou Gertsi, P ^a   Pardalos, G ^a   Kozeis, N ^b   Badouraki, M ^a   Kanakoudi Tsakalidou, F ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b Department of Ophthalmology ^*  (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; STEROID;

ADOLESCENT; ADULT; ARTHRALGIA; ARTICLE; CHILD; CLINICAL ARTICLE; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; EARLY DIAGNOSIS; FEMALE; GREECE; HAIR LOSS; HUMAN; INJECTION SITE ABSCESS; INJECTION SITE ERYTHEMA; INJECTION SITE PRURITUS; INJECTION SITE REACTION; JUVENILE RHEUMATOID ARTHRITIS; MALE; MENSTRUATION DISORDER; OBSERVATIONAL STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RESPIRATORY TRACT INFECTION; SCHOOL CHILD; SEPSIS; SKIN ABSCESS; TREATMENT RESPONSE; URTICARIA;

ADOLESCENT; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; CHILD; FEMALE; GREECE; HUMANS; LONGITUDINAL STUDIES; MALE; PROSPECTIVE STUDIES; RECURRENCE; RESPIRATORY TRACT INFECTIONS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; UVEITIS;

EID: 79952379405     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.3109/03009742.2010.517546     Document Type: Article

References (36)

1. Gartlehner G, Hansen RA, Jonas BL, Thieda P, Lohr KN. Biologics for the treatment of juvenile idiopathic arthritis: a systemic review and critical analysis of the evidence. Clin Rheumatol 2008;27:67-76. (Pubitemid 350182680)
2. Beresford MW, Baildam EM. New advances in the management of juvenile idiopathic arthritis. 2: The era of biologicals. Arch Dis Child Educ Pract Ed 2009;94:151-6.
3. Lovell DJ, Reiff A, Ilowite NT, Wallace CA, Chon Y, Lin SK, et al. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile idiopathic arthritis. Arthritis Rheum 2008;58:1496-504. (Pubitemid 351705939)
4. Horneff G, de Bock F, Foeldevari I, Girschick HJ, Michels H, Moebious D, et al. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German registry. Ann Rheum Dis 2009;68:519-25.
5. Prince FH, Twilt M, ten Cate R, van Rossum MA, Armbrust W, Hoppenrejis EP, et al. Long-term follow-up on effectiveness and safety of etanercept in JIA: the Dutch national register. Ann Rheum Dis 2009;68:635-41.
6. Furst DE, Schiff MH, Fleischmann RM, Strand V, Birbara CA, Compagnone D, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 2003;30:2569-71.
7. Lovell DJ, Ruperto N, Goodman S, Reiff A, Jung L, Jarosova K, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 2008;359:810-20.
8. Katsicas MM, Russo RA. Use of adalimumab in patients with juvenile idiopathic arthritis refractory to etanercept and/or infliximab. Clin Rheumatol 2009;28:985-8.
9. Petty RE, Southwood TR, Manners P, Baum J, Glass GN, Goldenberg J, et al. International League of Associations for Rheumatology Classification of Juvenile Idiopathic Arthritis: Second Revision, Edmonton, 2001. J Rheumatol 2004;31:390-2. (Pubitemid 38160763)
10. Reddy AR, Backhouse OC. Does etanercept induce uveitis? Br J Ophthalmol 2003;87:925.
11. Magni-Manzoni S, Ruperto N, Pistorio A, Sala E, Solari N, Palmisani E, et al. Development of validation of a preliminary definition of minimal disease activity in patients with juvenile idiopathic arthritis. Arthritis Rheum 2005;52:2092-102. (Pubitemid 40994332)
12. Wallace CA, Ruperto N, Giannini EH; Childhood Arthritis and Rheumatology Research Alliance; Pediatric Rheumatology International Trials Organization; Pediatric Rheumatology Collaborative Study Group. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol 2004;31:2290-4.
13. Lurati A, Salmaso A, Gerloni V, Gattinara M, Fantini F. Accuracy of Wallace criteria for clinical remission in juvenile idiopathic arthritis: a cohort study of 761 consecutive cases. J Rheumatol 2009;36:1532-5.
14. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile idiopathic arthritis. Arthritis Rheum 1997;40:1202-9. (Pubitemid 27430130)
15. Kanakoudi-Tsakalidou F, Tzimouli V, Pratsidou-Gertsi P, Chronopoulou E, Trachana M. The significance of persistent newly developed autoantibodies in JIA patients under long-term anti-TNF treatment. Cytokine 2008;42:293-7.
16. Rossi F, Di Dia F, Galipo A, Pistorio A, Valle M, Magni-Manzoni S, et al. Use of the Sharp and Larsen scoring methods in the assessment of radiographic progression in juvenile idiopathic arthritis. Arthritis Rheum 2006;55:717-23. (Pubitemid 44619184)
17. van Rossum M, Boers M, Zwinderman AH, van Soesbergen RM, Wieringa H, Fiselier TJ, et al. Development of a standardized method of assessment of radiographs and radiographic change in juvenile idiopathic arthritis. Arthritis Rheum 2005;9:2865-72. (Pubitemid 41369117)
18. Lovell DJ, Reiff A, Olcay Y, Schneider R, Nocton J, Stein LD, et al. Long-term safety and efficacy of etanercept in children with polyarticular course juvenile rheumatoid arthritis. Arthritis Rheum 2006;54:1987-94. (Pubitemid 43877949)
19. Lahdenne P, Vahasalo P, Honkanen V. Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study. Ann Rheum Dis 2003;62:245-7. (Pubitemid 36238089)
20. Smith JA, Thompson DJ, Whitcup SM, Suhler E, Clarke G, Smith S, et al. A randomized, placebo-controlled double-masked trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum 2005;53:18-23. (Pubitemid 40216347)
21. Weinblatt M, Keystone E, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti-tumor necrosis factor-a monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate. Arthritis Rheum 2003;48:35-45. (Pubitemid 36091645)
22. Biester S, Deuter C, Michels H, Haefner R, Kuemmerle-Deschner J, Doycheva D, et al. Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol 2007;91:319-24. (Pubitemid 46586527)
23. Tynjala P, Kotaniemi K, Lindahl P, Latva K, Aalto K, Honkanen V, et al. Adalimumab in juvenile idiopathic arthritis-associated uveitis. Rheumatology (Oxford) 2008;47:339-44. (Pubitemid 351267203)
24. Russo R A G, Katsicas MM. Clinical remission in patients with systemic juvenile idiopathic arthritis treated with anti-tumor necrosis factor agents. J Rheumatol 2009;36:1078-82.
25. Furst DE. The risk of infections with biologic therapies for rheumatoid arthritis. Semin Arthritis Rheum 2010;39:327-46.
26. Favalli EG, Desiati F, Atzeni F, Sarzi-Puttini P, Caporali R, Pallavicini FB, et al. Serious infections during anti-TNFa treatment in rheumatoid arthritis patients. Autoimmun Rev 2009;8:266-73.
27. Bennet AN, Peterson P, Zain A, Grumley J, Panayi G, Kirkham B. Adalimumab in clinical practice. Outcome in 70 rheumatoid arthritis patients, including comparison of patients with or without previous anti-TNF exposure. Rheumatology 2005;44:1026-31. (Pubitemid 41487177)
28. Burmester GR, Mease P, Dijkmans B A C, Gordon K, Lovell D, Panaccione R, et al. Adalimumab safety and mortality rates from global clinical trials in six immune-mediated inflammatory diseases. Ann Rheum Dis 2009;68:1863-9.
29. Foeldvari I, Nielsen S, Kummerle-Deschner J, Espada G, Horneff G, Bica B, et al. Tumor-necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results from a multinational survey. J Rheumatol 2007;34:1146-50. (Pubitemid 46774863)
30. Emery P, Seto Y. Role of biologics in early arthritis. Clin Exp Rheumatol 2003;21(Suppl 31): S191-3.
31. Smolen JS, Aletaha D, Steiner G. Does damage cause inflammation? Revisiting the link between joint damage and inflammation. Ann Rheum Dis 2009;68:159-62.
32. Vazquez-Cobian B, Flynn T, Lehman A. Adalimumab therapy for childhood uveitis. J Pediatr 2006;149:572-5. (Pubitemid 44468085)
33. Ilowite NT. Update on biologics in juvenile idiopathic arthritis. Curr Opin Rheumatol 2008;20:613-15.
34. Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, et al. Radiologic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo controlled, 52-week trial. Arthritis Rheum 2004;50:1400-11. (Pubitemid 38608061)
35. Hoff M, Kvien TK, Kalvesten J, Elden A, Haugeberg G. Adalimumab therapy reduces hand bone loss in early rheumatoid arthritis: exploratory analyses from the PREMIER study. Ann Rheum Dis 2009;68:1171-6.
36. Moots R, Taggart A, Walker D. Biologic therapy in clinical practice: enthusiasm must be tempered by caution. Rheumatology (Oxford) 2003;42:614-16. (Pubitemid 37220868)